Polaris Market Research recently updated its existing market research study on the report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021 – 2028” the report covers an exhaustive list of market tables and figures, thus providing in-depth analytical data for segments across different regions.
The global gene therapy market was valued at USD 1.46 billion in 2020 and is expected to reach USD 5.02 billion by 2028 to grow at a CAGR of 17.0% during the forecast period (2021 – 2028). The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.
Request for a sample copy at: https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample
- The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.
- Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.
- North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region
- The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020
North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period.
Have Any Query Or Specific Requirement? Feel Free To Ask Our Industry Experts At : https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst
List of Key Players
- Dimension Therapeutics
- Novartis AG
- Bluebird Bio
- Gilead Sciences Inc.
- Human Stem Cell Institute
- Spark Therapeutics
- Celgene Corporation
- Sangamo Biosciences
- Bristol Myer’s Squibb
- Celgene Corporation
Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region
Gene Therapy, Therapeutic Area Outlook (Revenue – USD Million, 2016 – 2028)
- Autoimmune Disorders
- Cardiovascular Diseases
- Dermatological Disorders
- Genetic Disorders
- Hematological Disorders
- Metabolic Disorders
- Muscle-related Diseases
- Oncological Disorders
- Ophthalmic Diseases
Gene Therapy, Vector Type Outlook (Revenue – USD Million, 2016 – 2028)
- Retroviral vectors
- Gamma-retroviral vectors
- Lentiviral vectors
- Adeno-associated virus vectors
- other viral vectors
- Retroviral vectors
- Other non-viral vectors
Gene Therapy, Approach Outlook (Revenue – USD Million, 2016 – 2028)
- Oncolytic Viral Therapy
Gene Therapy, Route of Administration Outlook (Revenue – USD Million, 2016 – 2028)
Gene Therapy, Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- Asia Pacific
- South Korea
- Central & South America
- Middle East & Africa
- Saudi Arabia
- South Africa
Find more research reports on Healthcare Industry by Polaris
Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027
Eosinophilic Esophagitis Drug Market Share, Size, Trends, Industry Analysis Report, By Product (Off-Label Drugs, Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan); By Diagnosis; By Treatment; By Regions; Segment Forecast, 2021 – 2028
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavour to deliver value-added business solutions to our customers.
Polaris Market Research